KRYS

Krystal BiotechB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$450.00

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$375.00

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$260.00

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-06

AI commentary

Post-earnings news tone is mixed-to-negative: company-reported operating results were strong, but recent coverage includes a negative gene-therapy-miss headline. A market-data page showed $351.82 regular-session pricing and $344.75 extended trading around the earnings report, while the RankAlpha anchor was $325.78 on August 5; attribution is not clean. Social coverage and verified analyst revisions are unavailable, so this remains a monitoring-oriented positive thesis rather than a high-conviction upgrade.

RankAlpha Sentiment Codex - 2026-08-06

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-14catalystPost-earnings estimate and reaction digestionMedium impact

The packet does not provide verified EPS or revenue surprise data, post-print analyst revisions, or target changes. Recent coverage includes both positive earnings highlights and a negative headline describing a gene-therapy miss, leaving near-term direction unresolved.

2026-11-04eventKB803 registrational readoutHigh impact

The fully enrolled IOLITE study of KB803 remains on track for a top-line data readout in Q4 2026, creating a potentially material clinical catalyst. [#8-K-2026-08-03](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/a2q26-ex991xpressrelease.htm)

2026-12-31eventVYJUVEK commercial execution and European expansionHigh impact

Q2 VYJUVEK global revenue was $119.2 million, up 24% year over year, with 95% gross margin, more than 730 reimbursement approvals, and over 640 prescribers. Spain and Italy launches are expected before year-end. [#8-K-2026-08-03](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/a2q26-ex991xpressrelease.htm)

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-06 • Updated nightlySource: Internal modelMethodology